Search results for: '2016 deal alliance review'

Provides a detailed understanding and analysis of how and why companies enter Big Pharma partnering deals

Genomics Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2018 to 2025

Companion Diagnostics Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2010 to 2025

Antibody Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2019 to 2025

Essential Benchmark Data for Dealmakers  | Global coverage | Updated to 2026 | 11+ years of royalty rates | Deal financials | Contract documents | Royalty rate trends

The Leading Partnering Intelligence Platform for Pharma, Biotech and Diagnostic Dealmakers

Ophthalmics Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals | Comprehensive deal directory 2019 to 2025

Global Generic Pharmaceutical Partnering Terms and Agreements 2010 to 2026 report provides a detailed understanding and analysis of how and why companies enter generic pharmaceutical partnering deals. 

Provides comprehensive understanding and unprecedented access to the animal health agreements entered into by the world's leading biopharma companies.